Trials / Completed
CompletedNCT00054873
Tezacitabine With or Without 5-Fluorouracil (5-FU) for Advanced Esophageal Cancer or Gastric Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Chiron Corporation · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of tezacitabine when given alone or in combination with 5-fluorouracil (5-FU) to subjects who have advanced esophageal or gastric adenocarcinoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tezacitabine | |
| DRUG | 5-fluorouracil |
Timeline
- Start date
- 2003-11-01
- Completion
- 2004-12-01
- First posted
- 2003-02-13
- Last updated
- 2006-07-11
Locations
29 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00054873. Inclusion in this directory is not an endorsement.